Surgical management of benign prostatic hyperplasia by thermotherapy and other emerging techniques: A review of the literature by the LUTS committee of the French Urological Association;Traitement chirurgical de l'hyperplasie bénigne de la prostate par thermothérapie et autres techniques émergentes: Revue de littérature du CTMH de l'AFU

Progres en Urologie

Volumn 22, Issue 2, 2012, Pages 87-92

  Barry Delongchamps, N ^a   Robert, G ^b   Descazeaud, A ^c,d   Cornu, J N ^e   Azzouzi, A R ^f   Haillot, O ^g   Devonec, M ^h   Fourmarier, M ⁱ   Ballereau, C ^j   Lukacs, B ^e   Dumonceau, O ^k   Saussine, C ^l   de la Taille, A ^m,n  

^a Institut Cochin   (France)

^b HÔPITAL PELLEGRIN   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF LIMOGES   (France)

^e HÔPITAL TENON   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF TOURS   (France)

^h HOSPICES CIVILS DE LYON   (France)

ⁱ CENTRE HOSPITALIER DU PAYS D AIX   (France)

^j Hôpital Privé de la Louvière   (France)

^k SAINT JOSEPH HOSPITAL   (France)

^l HÔPITAL CIVIL   (France)

^m HENRI MONDOR HOSPITAL   (France)

ⁿ INSERM   (France)

more..

Author keywords

Benign prostatic hyperplasia; Botulinium toxin; Ethanol injections; Radiofrequency; Urethral stent

Indexed keywords

CATHETER ABLATION; DIATHERMY; HUMAN; MALE; PROSTATE HYPERTROPHY; SHORT SURVEY;

CATHETER ABLATION; DIATHERMY; HUMANS; MALE; PROSTATIC HYPERPLASIA;

EID: 84856286824     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2011.08.029     Document Type: Short Survey

References (30)

1. Philipps B, Ball C, Sacket D, Benedoch D Straus S, Haynes B, et al. Oxford centre for evidence-based medicine levels of evidence 2001. http://www.cebm.net/.
2. Lourenco T., Armstrong N., N'Dow J., Nabi G., Deverill M., Pickard R. Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technol Assess 2008, 12:1-146.
3. Hoffman R.M., McDonald R., Monga M., Wilt T.J. Transurethral microwave thermotherapy vs transurethral resection for treating benign prostatic hyperplasic: a systematic review. BJU Int 2004, 94:1031-1036.
4. Gravas S., Laguna P., Ehrnebo M., Wagrell L., Mattiasson A., de la Rosette J.J., et al. Seeking for evidence that cell kill guided thermotherapy gives results not inferior to transurethral resection of prostate: results of a pooled analysis of 3 studies on feedback transurethral microwave thermotherapy. J Urol 2005, 174:1002-1006.
5. Hoffman R.M., Monga M., Elliot S., Macdonald R., Wilt T.J. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev 2007, 17(4):CD004135.
6. Floratos D.L., Kiemeney L.A., Rossi C., Kortmann B.B., Debruyne F.M., de La Rosette J.J., et al. Long-term followup of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. J Urol 2001, 165:1533-1538.
7. Ekstrand V., Westermark S., Wiksell H., Bergmann B., Cronwall K. Long-term clinical outcome of transurethral microwave thermotherapy (TUMT) 1991-1999 at Karolinska Hospital, Sweden. Scand J Urol Nephrol 2002, 36:113-118.
8. Mattiasson A., Wagrell L., Schelin S., Nordling J., Richthoff J., Magnusson B., et al. Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology 2007, 69:91-96.
9. Djavan B., Roehrborn C.G., Shariat S., Ghawidel K., Marberger M. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. J Urol 1999, 161:139-143.
10. Kellner D.S., Armenakas N.A., Brodherson M., Heyman J., Fracchia J.A. Efficacy of high-energy transurethral microwave thermotherapy in alleviating medically refractory urinary retention due to benign prostatic hyperplasia. Urology 2004, 64:703-706.
11. Gravas S., Laguna P., Kiemeney L.A., de la Rosette J.J. Durability of 30minutes high-energy transurethral microwave therapy for the treatment of BPH: a study of 213 patients with and without urinary retention. Urology 2007, 69:854-858.
12. Minardi D., Garafolo F., Yehia M., Minardi D., Garofalo F., Yehia M., et al. Pressure-flow studies in men with benign prostatic hypertrophy before and after treatment with transurethral needle ablation. Urol Int 2001, 66:89-93.
13. Zlotta A.R., Giannakopoulos X., Maehlum O., Ostrem T., Schuman C.C., et al. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003, 44:89-93.
14. Benoist N., Bigot P., Colombel P., Amie F., Haringanji C., Chautard D., et al. Tuna: clinical retrospective study addressing mid-term outcomes. Prog Urol 2009, 19:54-59.
15. Cimentepe E., Unsal A., Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. J Endourol 2003, 17:103-107.
16. Hindley R.G., Mostafid A.H., Brierly R.D., Harrison N.W., Thomas P.J., Fletcher M.S. The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate. BJU Int 2001, 88:217-220.
17. Hill B., Belville W., Bruskewitz R., Issa M., Perez-Marrero R., Roehrborn C., et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004, 171:2336-2340.
18. Kim T.S., Choi S., Rhew H.Y., Ahn J.H., Jang J.H., Cho M.H. Comparative study on the treatment outcome and safety of TURP, ILC, TUNA and TEAP for patients with benign prostatic hyperplasia. Korean J Urol 2006, 47:13-19.
19. Armitage J.N., Rashidian A., Cathcart P.J., Emberton M., van der Meulen J.H. The thermo-expandable metallic stent for managing benign prostatic hyperplasia: a systematic review. BJU Int 2006, 98:806-810.
20. Armitage J.N., Cathcart P.J., Rashidian A., De Nigris E., Emberton M., van der Meulen J.H. Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature. J Urol 2007, 177:1619-1624.
21. Masood S., Djaladat H., Kouriefs C., Keen M., Palmer J.H. The 12-year outcome analysis of an endourethral wallstent for treating benign prostatic hyperplasia. BJU Int 2004, 94:1271-1274.
22. Goya N., Ishikawa N., Ito F., Kobayashi C., Tomizawa Y., Toma H. Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results. J Urol 2004, 172:1017-1020.
23. Chiang P.H., Chuang Y.C., Huang C.C., Chiang C.P. Pilot study of transperineal injection of dehydrated ethanol in the treatment of prostatic obstruction. Urology 2003, 61:797-801.
24. Plante M.K., Marks L.S., Anderson R., Amling C., Rukstalis D., Badlani G., et al. Phase I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 2007, 177:1030-1035.
25. Grise P., Plante M., Palmer J., Martinez-Sagarra J., Hernandez C., Schettini M., et al. Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur Urol 2004, 46:496-501.
26. Magno C., Mucciardi G., Galì A., Anastasi G., Inferrera A., Morgia G. Transurethral ethanol ablation of the prostate (TEAP): an effective minimally invasive treatment alternative to traditional surgery for symptomatic benign prostatic hyperplasia (BPH) in high-risk comorbidity patients. Int Urol Nephrol 2008, 40:941-946.
27. Sakr M., Eid A., Shoukry M., Fayed A. Transurethral ethanol injection therapy of benign prostatic hyperplasia: four-year follow-up. Int J Urol 2009, 16:196-201.
28. Chuang Y.C., Chancellor M.B. The application of botulinum toxin in the prostate. J Urol 2006, 176:2375-2382.
29. Oeconomou A., Madersbacher H., Kiss G., Berger T.J., Melekos M., Rehder P. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol 2008, 54:765-775.
30. Maria G., Brisinda G., Civello I.M., Bentivoglio A.R., Sganga G., Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003, 62:259-264.